Neonatal Sepsis And Antibiotic Resistance: Emerging Challenges And Future Perspectives
DOI:
https://doi.org/10.52783/jns.v14.2710Keywords:
Neonatal sepsis, antibiotic resistance, multidrug-resistant bacteria, neonatal infections, antimicrobial stewardship, phage therapy, probiotics, alternative therapies, neonatal microbiome, bacterial pathogensAbstract
Neonatal sepsis remains a major cause of neonatal morbidity and mortality worldwide, particularly in low- and middle-income countries. The emergence of antibiotic-resistant bacterial strains has further complicated treatment options, leading to increased mortality and prolonged hospital stays. This review explores the epidemiology, risk factors, and common bacterial pathogens associated with neonatal sepsis. It also highlights the mechanisms of antibiotic resistance and current treatment strategies, including the limitations of broad-spectrum antibiotics. Additionally, we discuss the critical challenges in managing neonatal sepsis, such as the lack of neonatal-specific antibiotics and antibiotic stewardship gaps. Finally, future directions, including alternative therapies such as phage therapy, probiotics, and vaccines, are explored as potential solutions to combat neonatal sepsis and antibiotic resistance. Addressing these challenges requires a multidisciplinary approach to enhance infection control, improve antimicrobial stewardship, and develop novel therapeutic interventions to reduce the burden of neonatal sepsis.
Downloads
Metrics
References
WHO, 2022. Global Report on Neonatal Sepsis and Antimicrobial Resistance.
Fleischmann et al., 2021. "The Burden of Neonatal Sepsis: Epidemiology and Antimicrobial Resistance Trends." Lancet Infect Dis.
Laxminarayan et al., 2020. "Antimicrobial Resistance: The Growing Crisis in Neonatal Infections." JAMA Pediatrics.
Camacho-Gonzalez et al., 2019. "Early-Onset and Late-Onset Neonatal Sepsis: A Review." ClinPerinatol.
Zea-Vera & Ochoa, 2020. "Neonatal Sepsis in Developing Countries: A Systematic Review." Pediatrics.
UNICEF, 2021. "Neonatal Mortality and Global Health Challenges."
Schrag et al., 2018. "Group B Streptococcus and Neonatal Sepsis." N Engl J Med.
Dong et al., 2021. "Hospital-Acquired Infections in NICUs and Antimicrobial Resistance Trends." Front Microbiol.
Bizzarro et al., 2020. "Multidrug-Resistant Pathogens in Neonatal Sepsis: Global Insights." J Infect Dis.
Strunk et al., 2022. "Hospital-Acquired Neonatal Sepsis: Risk Factors and Prevention Strategies." J Perinatol.
Shane et al., 2019. "Neonatal Sepsis and Prematurity: A Dangerous Combination." Lancet Neonatology.
Verani et al., 2019. "Prolonged Rupture of Membranes and Risk of Neonatal Sepsis." Obstet Gynecol.
Greenberg et al., 2020. "The Role of Invasive Devices in Neonatal Infections." PediatrCrit Care Med.
Tzialla et al., 2018. "Impact of Antibiotic Use on Neonatal Gut Microbiota and Resistance." Front Pediatr.
CDC, 2021. "Infection Control and Antimicrobial Stewardship in Neonatal Units."
Mathur S, Jackson C, Urus H, Ziarko I, Goodbun M, Hsia Y, et al. A comparison of five paediatric dosing guidelines for antibiotics. Bull World Health Organ. 2020. Jun 1;98(6):406–412F. 10.2471/BLT.19.234310
Mathur S, Jackson C, Urus H, Ziarko I, Goodbun M, Hsia Y, et al. A comparison of five paediatric dosing guidelines for antibiotics. Bull World Health Organ. 2020. Jun 1;98(6):406–412F. 10.2471/BLT.19.234310
Sands K, Carvalho MJ, Portal E, Thomson K, Dyer C, Akpulu C, et al. ; BARNARDS Group. Characterization of antimicrobial-resistant gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries. Nat Microbiol. 2021. Apr;6(4):512–23. 10.1038/s41564-021-00870-7
Tamma et al., 2021. "Extended-Spectrum Beta-Lactamase and Carbapenemase-Producing Pathogens in Neonatal Sepsis." Clin Infect Dis.
Poole, 2018. "Efflux-Mediated Antimicrobial Resistance in Pseudomonas aeruginosa." Nat Rev Microbiol.
Costerton et al., 2019. "Bacterial Biofilms and Antibiotic Resistance in Neonatal Sepsis." Front Microbiol.
Chambers &Deleo, 2020. "Methicillin-Resistant Staphylococcus aureus: Mechanisms of Resistance." J AntimicrobChemother.
Davies & Davies, 2018. "Horizontal Gene Transfer and Antibiotic Resistance Evolution." MicrobiolMolBiol Rev.
Puopolo et al., 2022. "Neonatal Sepsis Guidelines and Empirical Therapy." JAMA Pediatr.
Verani et al., 2023. "Optimizing Neonatal Sepsis Management in NICUs." Clin Infect Dis.
Kollef et al., 2021. "Carbapenem-Resistant Bacteria and Novel Antibiotic Therapies." Lancet Infect Dis.
Falagas et al., 2020. "Polymyxins in Neonatal Infections: Risks and Benefits." Antimicrob Agents Chemother.
Bassetti et al., 2023. "Emerging Antibiotics for Multidrug-Resistant Neonatal Sepsis." Front Microbiol.
Manzoni et al., 2019. "Role of Lactoferrin in Preventing Neonatal Sepsis." Pediatrics. [30] Fowler et al., 2022. "Monoclonal Antibody Therapies for Neonatal Infections." Nat Rev Microbio
Gordillo Altamirano, F. L., & Barr, J. J. (2019). Phage therapy in the postantibiotic era. Clinical Microbiology Reviews, 32(2), e00066-18.
Kumar, R., Singh, S., & Dhillon, M. S. (2022). Challenges in the management of neonatal sepsis: The role of antibiotic stewardship. Pediatrics International, 64(3), 134-142.
Madhi, S. A., Dangor, Z., Heath, P. T., Schrag, S., Izu, A., Sobanjo-Ter Meulen, A., & Kwatra, G. (2020). Considerations for a Group B Streptococcus vaccine for pregnant women. The Lancet Infectious Diseases, 20(5), e125-e135.
Shah, B. A., Singh, G., Naik, M. A., & Dhawan, B. (2020). Neonatal sepsis: An overview with an emphasis on antibiotic resistance. The Indian Journal of Pediatrics, 87(2), 108-116.
Underwood, M. A. (2019). Probiotics and the prevention of necrotizing enterocolitis. Journal of Pediatric Surgery, 54(4), 405-412.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
